Clinical Trial Update: Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) [Phase 3]

View source ↗

Summary

Phase 3 trial update for daprodustat (a novel prolyl hydroxylase inhibitor) in anemia of chronic kidney disease (ASCEND-D) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Daprodustat (daprodustat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia, Aspergillosis, Allergic Bronchopulmonary | Phase 3 | Status: COMPLETED | Results posted: 2021-12-03